$69.19
-0.28-0.41%
Last update: 10:29 AM
15 minutes delayed
Biomarin Pharmaceutical reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Biomarin Pharmaceutical using advanced sorting and filters.
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Jun 2024 | 2024-08-05 | $0.96 | $0.35 | 174.3 % |
Mar 2024 | 2024-04-24 | $0.71 | $0.34 | 108.8 % |
Dec 2023 | 2024-02-22 | $0.49 | $0.23 | 113.0 % |
Sep 2023 | 2023-11-01 | $0.46 | $0.22 | 109.1 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Jun 2024 | 2024-08-05 | $712.03M | $661.23M | 7.68 % |
Mar 2024 | 2024-04-24 | $648.83M | $651.79M | -0.45 % |
Dec 2023 | 2024-02-22 | $646.21M | $636.67M | 1.50 % |
Sep 2023 | 2023-11-01 | $581.33M | $608.33M | -4.44 % |
Biomarin Pharmaceutical (BMRN) is scheduled to report earnings on October 30, 2024. The last reported earnings were for reported on August 5, 2024 for Q2.
The Actual EPS was $0.96, which beat the estimate of $0.35.
The Actual Revenue was $712M, which beat the estimate of $661.2M.
Browse earnings estimates, EPS, and revenue on all stocks.